key: cord-0684883-67pfen3n authors: Patel, Karan; Choudhury, Ananya; Hoskin, Peter; Varughese, Mohini; James, Nicholas; Huddart, Robert; Birtle, Alison title: Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19 Pandemic – Rapid Review date: 2020-04-24 journal: Clin Oncol (R Coll Radiol) DOI: 10.1016/j.clon.2020.04.005 sha: 1fb662f382f5c37b249657e3d71c1bb89de4f1e1 doc_id: 684883 cord_uid: 67pfen3n Abstract The current COVID-19 pandemic presents a substantial obstacle to cancer patient care. Data from China as well as risk models suppose that cancer patients, particularly those on active, immunosuppressive therapies are at higher risks of severe infection from the illness. In addition, staff illness and restructuring of services to deal with the crisis will inevitably place treatment capacities under significant strain. These guidelines aim to expand on those provided by NHS England regarding cancer care during the coronavirus pandemic by examining the known literature and provide guidance in managing patients with urothelial and rarer urinary tract cancers. In particular, they address the estimated risk and benefits of standard treatments and consider the alternatives in the current situation. As a result, it is recommended that this guidance will help form a framework for shared decision making with patients. Moreover, they do not advise a one-size-fits-all approach but recommend continual assessment of the situation with discussion within and between centres. The current COVID-19 pandemic presents a substantial obstacle to cancer patient care. Data from China as well as risk models suppose that cancer patients, particularly those on active, immunosuppressive therapies are at higher risks of severe infection from the illness. In addition, staff illness and restructuring of services to deal with the crisis will inevitably place treatment capacities under significant strain. These guidelines aim to expand on those provided by NHS England regarding cancer care during the coronavirus pandemic by examining the known literature and provide guidance in managing patients with urothelial and rarer urinary tract cancers. In particular, they address the estimated risk and benefits of standard treatments and consider the alternatives in the current situation. As a result, it is recommended that this guidance will help form a framework for shared decision making with patients. Moreover, they do not advise a one-sizefits-all approach but recommend continual assessment of the situation with discussion within and between centres. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly virulent, establishing the COVID-19 pandemic within three months of the first case [1] . With the caveat of a small and heterogenous study population [2, 3] , data from China infers that patients with cancer have higher incidence and severity of the illness [4, 5] . Those undergoing chemotherapy or surgery may have a further risk of severe events such as invasive ventilation and death [4] . Notably, risk models propose that most oncology patients possess an at least five percent mortality risk if infected with COVID-19 -equal to or greater than the benefits of many adjuvant regimens [6] . Service disruption including reduced access to theatres as well as high dependency care [7] is also expected to heavily impact cancer care. NHS England guidelines written in response to the extreme threat posed by COVID-19 advise the categorisation of cancer treatments according to the intent and risk-benefit ratio (tables 1 -3). They also advocate considering less resource-intensive regimens, accounting for other patient risk factors such as age, cardiac and chest disease, offering treatment-breaks where appropriate, using growth factors to reduce neutropaenia and prescribing hypofractionated radiotherapy regimens where possible [8] . The aim of this review is to place these guidelines into clinical context for patients with urothelial cancers during this unprecedented time. As per Gillessen and Powles, who have submitted guidance in European Urology for systemic treatment [9] , these recommendations reflect the published literature but do not endorse a one-size-fits-all approach. Over the coming weeks, each department will have unique stresses and resource issues where decision-making will require a level of pragmatism and fluidity out with these guidelines. Muscle-invasive bladder cancer, T2 -T4a, is treated via radical cystectomy or radiotherapy in conjunction with radiosensitisation [10, 11] . For locally advanced and metastatic disease, first line immunotherapy can be offered to those PDL-1 positive where cisplatin is unsuitable [12] . Second line options include taxane-based regimens [13] or atezolizumab [14] . Management of rarer urinary tract pathologies is also discussed below. Neoadjuvant chemotherapy before radical cystectomy or radical radiotherapy Neoadjuvant chemotherapy offers a 5% improvement in overall survival at five years [15] . Although deferral of patients' definitive treatment using neoadjuvant chemotherapy may seem strategically advantageous, the potential period of immunosuppression is six to nine weeks depending on regimen used. Additionally, dates of radical treatment may be threatened because of illness from treatment. Consequently, omission of neoadjuvant chemotherapy should be considered -priority level 4. Radical cystectomy is a valid treatment option for younger fitter patients needing curative therapy -priority level 2. However in the present situation, the risks are substantial for older, less fit patients who often have significant comorbidities and a high risk of death from hospital acquired COVID-19. Acquisition of randomised, phase III data comparing radical cystectomy and chemo-radiotherapy has proven challenging [16] . In its absence, retrospective nonrandomised trials have shown radical radiotherapy to offer very similar cancer-specific outcomes to cystectomy despite older radiation techniques and minimal use of concurrent chemotherapy [17] [18] [19] . Chemo-radiotherapy has also demonstrated comparable outcomes [20] and even improved overall survival [21] to surgery more recently, and is accepted as valid alternative by the joint EAU-ESMO consensus panel [22] and NICE [10] . In the current pandemic, bladder preservation therapy offers a sound choice for patients. NICE recommend adjuvant combination cisplatin chemotherapy after surgery for muscle-invasive or lymph-nodepositive urothelial bladder cancer where neoadjuvant chemotherapy was deemed unsuitable [10] . A meta-analysis observing the effect of adjuvant chemotherapy demonstrated an absolute increase in overall survival by 9% at three years [23] . However, patients aged 40 and over possess a greater risk of death if infected with COVID-19 than the benefit offered by adjuvant treatment [6] . Therefore chemotherapy post-cystectomy is not advised for most -priority level 4. Radiosensitisation with carbogen and nicotinamide or Mitomycin C and 5-fluorouracil (MMC-5FU) via the BCON and BC2001 trials has been shown to improve loco-regional recurrence-free and overall survivals [24, 25] . Although difference in overall survival with addition of MMC-5FU to radiotherapy was non-significant (p=0.16), muscle-invasive recurrence essentially halved [25] . In addition, improvement in bladder cancer specific survival became significant and the salvage cystectomy rate reduced to 11% with longer follow-up [26] . Carbogen and nicotinamide would be ideal radiosensitisers at present, especially in patients with significant necrotic areas in tumour [27] , because of their lack of immunosuppression. However, most radiotherapy departments do not have BCON up and running. Given the worldwide shortage of Mitomycin C, weekly gemcitabine [28] is an acceptable alternative and has been used as a standard option with 20 fraction radiotherapy in the RAIDER trial, a Randomised phase II trial of Adaptive Image guided standard or Dose Escalated tumour boost Radiotherapy in the treatment of transitional cell carcinoma of the bladder. Radiosensitisation cures muscle invasive bladder cancer and reduces numbers of salvage cystectomies, and is recommended at the highest priority -priority level 1. No statistically significant differences in locoregional disease-free survival or toxicity were seen between the conventionally (64 Gy in 32 fractions) and hypofractionated (55 Gy in 20 fractions) treated groups within the BC2001 and BCON trials [24, 25] . A meta-analysis by Porta et al. confirmed that hypofractionated radiotherapy was noninferior, and possibly superior, to conventionally fractionated radiotherapy for overall survival and late toxicity. Moreover, the hypofractionated population possessed better rates of invasive locoregional control [29] . Hence, hypofractionated radiotherapy is recommended ideally with a radiosensitiser where radical treatment is appropriatepriority level 1 (soft tissue image guidance (e.g. with cone beam CT) significantly improves accuracy and should be maintained whenever possible). Weekly radiotherapy in the form of 36Gy in six fractions or 21Gy in three fractions on alternate days has been shown as effective regimens in patients unsuitable for daily radical radiotherapy -albeit with limited long-term data [30, 31] . The Hypofractionated bladder Radiotherapy with or without image guided adaptive planning (HYBRID) study reported over 70% of patients achieving local control at 3 months in an unfit patient group [32] . In the event of significantly reduced staffing and capacity, 21 Gy in three fractions or 36Gy in six fractions may be considered in patients unsuitable for or when daily radiotherapy is unavailable. Cisplatin-containing chemotherapy, either as gemcitabine-cisplatin or methotrexate, vinblastine, adriamycin and cisplatin is the recognised standard in this setting [10, 11] . A study comparing the two demonstrated similar response rates of over 50% but a better side-effect profile with gemcitabine-cisplatin [33] . Keynote-052 observed an objective response rate of 24% with pembrolizumab in 370 patients with metastatic bladder cancer unfit for cisplatin [34] . Given the change in risk/benefit of palliative chemotherapy during the COVID-19 pandemic, patients with slowly growing metastatic disease should be observed; with chemotherapy reserved for rapidly progressive disease, and patients counselled specifically for the increased risk of COVID complications leading to death. Overall, immunotherapy should be the primary choice in PDL1 positive disease but the possibility of severe COVID-19 infection mimicking immunotherapy-induced pneumonitis should be recognised. In the absence of PDL1 positivity, chemotherapy remains an option for symptomatic control depending on capacity levels -priority level 4. Studies examining the efficacy of second line treatment are highly dependent on the characteristics of participants. NICE has removed approval for Pembroluzimab from 15 th April 2020 but atezoluzimab remains available via the Cancer Drugs Fund for patients who have had platinum-containing chemotherapy. This is predicated on the IMvigor studies [10] . In IMvigor 211, atezolizumab exhibited more durable response but not an improved overall survival compared to chemotherapy [35] . Four weekly atezolizumab may be considered in view of reduced hospital visits and lack of immunosuppression -priority level 4. Overall, the risk-benefit ratio of second line single agent chemotherapy is questionable in most cases -priority level 6. Upper tract urothelial carcinomas are rare [37] with treatment data previously lacking. The POUT trial recently addressed this paucity and observed a benefit of 17% on three-year disease-free survival following adjuvant gemcitabine-platinum for completely resected pT2-T4 pN0-N3 M0 or pTany N1-3 M0 disease [38] . Accordingly, postnephroureterectomy chemotherapy should be discussed with this patient cohort -priority level 3. The prognosis of small cell carcinoma remains poor. Previous literature has shown an important role for the use of neoadjuvant chemotherapy prior to surgery or radiotherapy to downstage and increase overall survival [39] [40] [41] . more Recent studies have not demonstrated differenced in survival rates between surgery and radiotherapy [42, 43] . Thus a conservative approach is warranted currently -priority level 2. In metastatic disease, a median overall survival of 15 months was seen with both cisplatin-and carboplatin-based regimens [43] -priority level 4. Pure squamous cell carcinomas of the urinary tract are relatively chemo-resistant and the peri-operative systemic therapy is not well-established [44] -priority level 6. Data describing perioperative chemotherapy in primary bladder adenocarcinoma is scarce. Vetterlain et al. found that neoadjuvant chemotherapy reduced the incidence of regional or distal disease at time of surgery but had no statistically significant effect on overall survival [45] . A retrospective study in Korea suggested a modest benefit with chemotherapy in the metastatic setting [46] -priority level 6. The COVID-19 pandemic presents a significant challenge for cancer care and patient safety. Timely and thorough planning would seem paramount in order to maintain essential services and vital treatments. Examining the efficacy and toxicity of treatments at the earliest opportunity will allow departments to determine which therapies to prioritise, what services to restructure in order to help key areas and most importantly which patients will derive the most benefit and least harm. Fortunately, the evidence base for anti-cancer therapies is relatively robust, which facilitates decisionmaking. This review highlights the literature underpinning the treatments used for urothelial cancers and provides a framework to aid patient discussions and treatment decisions (table 4) . Overall, prioritisation of curative treatments is advised. Any set of recommendations cannot encapsulate all possible scenarios and liaison within and between centres is strongly advocated. Lastly, submission of information to local and national data sets is also encouraged in order to later evaluate the impact of COVID19-related treatment decisions on outcomes. Priority level 1 • Curative therapy with a high (>50%) chance of success • Adjuvant (or neo) therapy which adds at least 50% chance of cure to surgery or radiotherapy alone or treatment given at relapse • Elective surgery can be delayed for 10-12 weeks with no predicted negative outcome WHO Director-General's opening remarks at the media briefing on COVID-19-11 Risk of COVID-19 for cancer patients Risk of COVID-19 for patients with cancer Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Clinical Characteristics of 138 Hospitalized Patients With Novel Coronavirus-Infected Pneumonia in Wuhan, China Estimating risks from COVID-19 in adult cancer patients Forecasting critical care bed requirements for COVID-19 patients in England. Centre for Mathematical Modelling of Infectious Disease -nCoV Working Group Clinical guide for the management of non-coronavirus patients requiring acute treatment: Cancer Advice for medical oncology care of urological cancer patients during the COVID-19 Editorial seen ahead of publication date in European Urology (Eur Urol) -personal communication of accepted manuscript by author National Institute for Health and Clinical Excellence. Bladder Cancer: Diagnosis and Management. NICE Guideline 2 -Full guideline, Updated information Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up Bladder cancer -everything NICE says in an interactive flowchart: First-line chemotherapy managing-locally-advanced-or-metastatic-bladdercancer.xml&content=view-node%3Anodes-second-line-treatment [accessed Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration Clinical and patient-reported outcomes of SPARE -a randomised feasibility study of selective bladder preservation versus radical cystectomy Similar Treatment Outcomes for Radical Cystectomy and Radical Radiotherapy in Invasive Bladder Cancer Treated at a United Kingdom Specialist Treatment Center A 10-Year Retrospective Review of a Nonrandomized Cohort of 458 Patients Undergoing Radical Radiotherapy or Cystectomy in Yorkshire Curative Therapy for Bladder Cancer in Routine Clinical Practice: A Population-based Outcomes Study Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic Radical cystectomy versus organ-sparing trimodality treatment in muscleinvasive bladder cancer: A systematic review of clinical trials EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort †: Under the Auspices of the EAU-ESMO Guidelines Committees Adjuvant chemotherapy for invasive bladder cancer (individual patient data). The Cochrane Database of Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer BC2001 long-term outcomes: A phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer Necrosis predicts benefit from hypoxiamodifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer Hypo-Fractionation in Muscle-Invasive Bladder Cancer: An Individual Patient Data (IPD) Meta-Analysis of the BC2001 and BCON Trials A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09 Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment OC-0058: Clinical outcomes of the first rct of adaptive radiotherapy in bladder cancer (HYBRID CRUK/12/055) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study First-line pembrolizumab in cisplatinineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial Palliative Radiation Therapy in Bladder Cancer-Importance of Patient Selection: A Retrospective Multicenter Study Upper tract urothelial neoplasms: incidence and survival during the last 2 decades Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial Phase II Clinical Trial of Neoadjuvant Alternating Doublet Chemotherapy With Ifosfamide/Doxorubicin and Etoposide/Cisplatin in Small-Cell Urothelial Cancer Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic Downstaging and Long-term Outcomes: Results from a Retrospective Study at the MD Anderson Cancer Center Locoregional Small Cell Carcinoma of the Bladder: Clinical Characteristics and Treatment Patterns Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology: Neoadjuvant CTX and Bladder Cancer Variants Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee • Karan Patel has no declarations or conflict of interests • Mohini Varughese has no conflicts of interests relevant to this submission • Nick James performs consultancy work with Merck and AstraZeneca plus trial funding (to institution not personal from AstraZeneca (AZ) Bristol advisory Squibb, Janssen, Bayer and Nektar. He is partner in Cancer centre London Acknowledgements: • Peter Hoskin and Ananya Choudhury are supported by the NIHR Manchester Biomedical Research Centre • Robert Huddart is supported by ICR/Royal Marsden Hospital NIHR Biomedical centre • Nicholas James is supported by ICR/Royal Marsden Hospital NIHR